Last $26.45 USD
Change Today +0.145 / 0.55%
Volume 754.4K
MASI On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

masimo corp (MASI) Snapshot

Open
$26.51
Previous Close
$26.30
Day High
$26.79
Day Low
$25.55
52 Week High
01/24/14 - $32.20
52 Week Low
08/8/14 - $19.30
Market Cap
1.4B
Average Volume 10 Days
420.9K
EPS TTM
$1.03
Shares Outstanding
52.4M
EX-Date
11/23/12
P/E TM
25.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for MASIMO CORP (MASI)

masimo corp (MASI) Related Businessweek News

No Related Businessweek News Found

masimo corp (MASI) Details

Masimo Corporation, a medical technology company, develops, manufactures, and markets various noninvasive patient monitoring products worldwide. The company offers Masimo Signal Extraction Technology (SET), which provides the capabilities of measure-through motion and low perfusion pulse oximetry to address the primary limitations of conventional pulse oximetry; and Masimo rainbow SET products that monitor multiple blood measurements, including oxygen content, carboxyhemoglobin, methemoglobin, hemoglobin, pleth variability index, respiration rate, Halo Index, and In Vivo Adjustment. It develops, manufactures, and markets a family of patient monitoring solutions comprising monitors, circuit boards, sensors, and cables; Root, a patient monitoring and connectivity platform; Masimo Patient SafetyNet, a remote monitoring and clinician notification solution; and various software products. The company also provides line filters, cannulas, and mainstream adapters; and wafer epitaxy, foundry, and device fabrication services to biomedical, telecommunications, consumer products, and other markets, as well as develops and manufactures ultra-compact mainstream and sidestream capnography, and gas monitoring technologies. Masimo Corporation sells its products to hospitals, emergency medical response organizations, physician offices, veterinarians, long term care facilities, consumers, and alternate care market through its direct sales force and distributors, as well as to original equipment manufacturer partners. The company was founded in 1989 and is headquartered in Irvine, California.

3,139 Employees
Last Reported Date: 02/14/14
Founded in 1989

masimo corp (MASI) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $712.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $334.4K
President of Worldwide Oem Business & Corpora...
Total Annual Compensation: $335.7K
President of Worldwide Sales & Marketing and ...
Total Annual Compensation: $332.4K
Chief Information Officer
Total Annual Compensation: $329.2K
Compensation as of Fiscal Year 2013.

masimo corp (MASI) Key Developments

Masimo Announces Global Launch of Multigas Monitoring for the Root Patient Monitoring and Connectivity Platform

Masimo announced FDA 510(k) clearance and CE Mark of ISA OR+ multigas monitoring, a Masimo Open Connect (MOC-9) Module for the Root patient monitoring and connectivity platform. During general anesthesia, the ISA OR+ monitors the inhaled and exhaled concentration of five anesthetic gas agents (Sevoflurane, Isoflurane, Halothane, Desflurane, Enflurane), carbon dioxide (CO2), nitrous oxide (N2O), and oxygen (O2), in addition to respiration rate. When technology modules are connected with Root, multiple additional parameters are available including Masimo SET® pulse oximetry, noninvasive and continuous hemoglobin (SpHb), PVI, SedLine brain function monitoring, and O3 Regional Oximetry. Key features and benefits of ISA OR+ include: Requires only 50 ml sampling flow to support monitoring - Time-saving in critical situations with virtually no warm-up time and full accuracy performance in less than 20 seconds - Automatic anesthetic agent identification - Supports monitoring patients with high respiration rates, up to 150 bpm - Low-power consumption and automatic temperature and pressure compensation - Provides minimal alveolar concentration (MAC), which is calculated from the measured anesthetic agents and N2O - Appropriate for monitoring adult, pediatric, or infant patients in a range of clinical environments including the operating room and intensive care unit - Compatible with Masimo's Nomoline Adapter and the Nomoline Airway Adapter Set to interface with endotracheal tubing. O3 Regional Oximetry is FDA 510(k) pending and is not available for sale in the United States.

Masimo Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 01:00 PM

Masimo Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 01:00 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States.

Masimo Corporation Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 27, 2014; Updates Financial Guidance for Fiscal 2014; Provides Effective Tax Rate Guidance for the Fourth Quarter of 2014

Masimo Corporation announced unaudited consolidated earnings results for the third quarter and nine months ended September 27, 2014. For the quarter, the company reported total revenue of $144,118,000, operating income of $22,268,000, income before provision for income taxes of $21,702,000, operating income was $22,268,000, net income attributable to the company's stockholders of $14,863,000 or $0.27 diluted per share against total revenue of $131,447,000, operating income of $20,743,000, income before provision for income taxes of $20,067,000, operating income of $20,743,000, net income attributable to the company's stockholders of $15,602,000 or $0.27 diluted per share a year ago. For the nine months, the company reported total revenue of $424,856,000, operating income of $70,866,000, income before provision for income taxes of $70,823,000, operating income was $70,866,000 net income attributable to the company's stockholders of $51,297,000 or $0.91 diluted per share against total revenue of $404,811,000, operating income of $67,064,000, income before provision for income taxes of $63,824,000, operating income of $67,064,000, net income attributable to the company's stockholders of $49,068,000 or $0.85 diluted per share a year ago. Net cash provided by operating activities was $66,823,000 and purchases of property and equipment was $66,847,000 against net cash provided by operating activities of $48,210,000 and purchases of property and equipment of $6,910,000 a year ago. Increase in intangible assets was $2,779,000 against $2,986,000 a year ago. The company is providing updated financial guidance for fiscal 2014. For the year, the company now expects total revenue to be approximately $585 million, including product revenue of approximately $556 million and royalty revenue of approximately $29 million. This represents a decline in the prior guidance for total 2014 revenues of approximately $588 million to $593 million, which included product revenues of $560 million to $565 million and royalty revenue of approximately $28 million. Despite the reduction in total product revenue and partially offsetting increase in royalty revenue guidance, the company expects GAAP earnings per diluted share to be approximately $1.28, within the prior range of $1.24 to $1.30. The guidance set forth above is an estimate only and actual performance could differ. The company continues to expect effective tax rate will be in the range of approximately 25% to 26%. For the fourth quarter of 2014, the company continues to expect effective tax rate will be in the range of approximately 25% to 26%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MASI:US $26.45 USD +0.145

MASI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CAS Medical Systems Inc $1.80 USD +0.06
Chemed Corp $106.84 USD -0.87
CONMED Corp $44.05 USD +0.77
Hutchinson Technology Inc $3.44 USD -0.05
Integra LifeSciences Holdings Corp $52.49 USD +0.95
View Industry Companies
 

Industry Analysis

MASI

Industry Average

Valuation MASI Industry Range
Price/Earnings 24.6x
Price/Sales 2.6x
Price/Book 4.9x
Price/Cash Flow 22.7x
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MASIMO CORP, please visit www.masimo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.